tbuckley/cabot-search huggingface dataset:
PTH-116 Time to Achieve Competency in Lower Gastrointestinal Polypectomy in The United Kingdom, A Retrospective Analysis
Authors: A Rajendran, S Thomas-Gibson, P Bassett, P Dunckley, N Sevdalis, A Haycock
Journal: Gut (2016)

<h3>Introduction</h3> Directly Observed Polypectomy Skills (DOPyS) is a validated tool used to assess polypectomy skills in the UK. The overall competency for polypectomy is graded on a scale of 1 to 4 and is used to certify trainees for level 1 polypectomy (size &lt; 1 cm) &amp; level 2 polypectomy (size 1–2 cm). Trainees are certified as competent if they achieve grades 3 or 4 for more than 90% of their last 4 consecutive DOPyS. We aimed to analyse time required for a trainee to progress from DOPyS score 1 to 4 <h3>Methods</h3> Retrospective data from the e-portfolio of 707 (4965 DOPyS) trainees from Jan 2009 to Sept 2015 was examined. A dataset of 24 trainees who had documented DOPyS overall score of 1 (CS1), 2 (CS2), 3 (CS3) and 4 (CS4) was recovered. For the purpose of the analysis only those trainees (n = 8) who started out at CS1 were included. 16 were excluded from analysis as they started at a higher level. Primary outcome was number of days taken by each trainee to reach the competency levels (i.e. CS2, CS3 and CS4). The proportion of trainees reaching each level was examined using Kaplan-Meier analysis to show the proportion reaching this level over time. Time taken for 25%, 50% and 75% of trainees to reach the desired level was calculated. <h3>Results</h3> <b>Table</b> shows time taken for 25%, 50% and 75% of trainees to reach each of the levels. The results show 50% reach CS2 after 91 days and CS3 after 112 days. It took 191 days for half of trainees to reach level CS4. <h3>Conclusion</h3> 75% of trainees analysed reach an overall competency of 4 in 324 days. In the UK DOPyS score 3 or 4 are required to start applying for provisional/full certification and in our cohort 75% of trainees analysed achieved it in a time frame of 6 months to a year. Further prospective studies analysing time taken, procedure numbers &amp; associated factors are needed to assess the learning curve for polypectomy &amp; implement changes to improve efficiency in training <h3>Limitation</h3> The retrospective data and the small numbers are the limitations of the study <h3>Disclosure of Interest</h3> None Declared
OC-062 Real Life Data on Sofosbuvir/Ledipasvir for 8 Weeks in Genotype 1 Treatment Naive, Non Cirrhotic Patients in the North East of Scotland: Abstract OC-062 Table 1
Authors: P Dundas, A Fraser, S English, L McLeman
Journal: Gut (2016)

<h3>Introduction</h3> Studies have identified groups of patients with Genotype 1 HCV infection who may achieve greater than 90% SVR 12 with only 8 weeks of treatment with Sofosbuvir/Ledipasvir (Sof/Led) (ION3 1). Patients in clinical trials tend to be highly selected and therefore our aim was to explore if the SVRs that can be achieved by this shortened duration of treatment in a ‘real life’ setting match the experience in the trials. <h3>Methods</h3> Our local guidelines state that Genotype 1, non cirrhotic, treatment naive patients should receive 8 weeks of Sof/Led with the addition of Ribavirin if the viral load is &gt;10 million iu/ml. Data on all patients commenced on Sof/Led between January and November 2015 was collected prospectively. Cirrhosis was defined as a fibroscan &gt;12.5 kpa. <h3>Results</h3> In total 42 patients have received treatment with Sof/Led for 8 weeks. Of the 42 patients 26 (62%) were male. The average age was 43 years (range 18–78). Average fibroscan score was 5.6 kpa (range 2.9–10.2). There were 4 patients with a fibroscan &gt;9 (classified as F3). All were treatment naive. Opiate substitution therapy was prescribed in 6/42 (14%). The viral load distribution was &lt;10,000 iu/ml – 5/42 (12%), 10001 iu/ml – &lt;10 M iu/ml –34/42 (81%), &gt;10 M–3/42 (7%). To date all patients have completed treatment (100%). Table 1 outlines the end of treatment (EOT), Week 4 SVR (SVR 4) and Week 12 SVR (SVR 12) data. The 2 patients ‘unknown’ were lost to follow up they completed treatment but did not attend for post treatment bloods. SVR 12 data will be available for all patients at the time of presentation. <h3>Conclusion</h3> Treatment with 8 weeks of Sofosbuvir/Ledipasvir ± ribavirin is well tolerated with few side effects or premature treatment discontinuations. Our data suggest that the SVRs rates with shortened duration of therapy achieved in clinical trials are achievable in ‘real life’ settings. <h3>Reference</h3> 1 Kowdley KV, <i>et al</i>, Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>N Engl J Med</i>. 2014 May 15;<b>370</b>(20):1879–88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10. <h3>Disclosure of Interest</h3> None Declared
Are Echocardiography and CMR Really Discordant in Mitral Regurgitation?
Authors: Vandana Sachdev, Hwaida Hannoush, Stanislav Sidenko, Shahryar G. Saba, Pamela Sears-Rogan, W. Patricia Bandettini, Alessandra Brofferio, Sujata M. Shanbhag, Cynthia L. Brenneman, Keith A. Horvath, Myron A. Waclawiw, Andrew E. Arai
Journal: JACC. Cardiovascular imaging (2016)
Allogeneic Stem Cell Transplantation in 59 Patients with Adlut T-Cell Leukemia/Lymphoma-A Single center’s 13 Years Experience-
Authors: Nobuaki Nakano, Yoshifusa Takatsuka, Shogo Takeuchi, Masahito Tokunaga, Ayumu Kubota, Mayumi Tokunaga, Takahiro Itoyama, Torahiko Makino, Atae Utsunomiya
Journal: Blood (2011)
Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma
Authors: Spiros Kotopoulis, Endre Stigen, Mihaela Popa, Mireia Mayoral Safont, Andrew Healey, Svein Kvåle, Per Sontum, Bjørn Tore Gjertsen, Odd Helge Gilja, Emmet McCormack
Journal: Journal of Controlled Release (2016)
An International Multicentric Trial with Fludarabine Plus Cyclosphosphamide in B-Cell Chronic Lymphocytic Leukemia (CLL) “Up Front”: Second Interim Analysis.
Authors: Fernando Bezares, Cecilio Jait, Daniel Caviglia, Daniel Bhar, Andrea Rodriguez, Norma Pilnik, Virginia Prates, Francisco Lastiri, D. del Carpio, Antonio A. Carrasco-Yalan, Sergio Giralt
Journal: Blood (2006)
Through-the-mesh technique after endoscopic ultrasonography-guided hepaticogastrostomy: a novel re-intervention method
Authors: Kosuke Minaga, Mamoru Takenaka, Takeshi Miyata, Yasuhiro Ueda, Masayuki Kitano, Masatoshi Kudo
Journal: Endoscopy (2016)

Endoscopic ultrasonography-guided hepaticogastrostomy (EUS-HGS) is increasingly used to manage failed endoscopic biliary drainage in patients with malignant biliary obstruction [1] [2] [3]. A recent study showed that, for EUS-HGS, a stent ≥ 3 cm in length in the luminal portion may be suitable to prevent stent migration and achieve long-term stent patency [4]. However, such a placement can sometimes make re-intervention difficult. Here, we describe a novel re-intervention technique for HGS stent occlusion.
FRI0496 Long Term Safety and Efficacy of Anakinra in Adult Patients with Refractory Recurrent Idiopathic Pericarditis
Authors: K. Antonatou, P. Vasileiou, C. Koutsianas, G. Lazaros, D. Vassilopoulos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Our previous open label study has shown that IL-1 inhibition with anakinra was an efficacious, safe and steroid-sparing agent for the short term treatment of refractory recurrent idiopathic pericarditis in adults. However long term data are not available in such patients. <h3>Objectives</h3> The aim of this study, which is a follow-up of the initial cohort of patients, was to assess the long term safety and efficacy of Anakinra in adult patients with refractory recurrent idiopathic pericarditis. <h3>Methods</h3> Eleven patients with treatment-resistant idiopathic recurrent pericarditis were included (a new patient was added to the initial cohort of 10 patients). All patients were resistant and/or intolerant to previous treatment with aspirin and/or NSAIDs, colchicine and corticosteroids (CS) while two (18%) had failed azathioprine therapy. Initially all were treated with daily subcutaneous injections of Anakinra (100 mg) with gradual tapering of the administered dose (daily for 6 months, followed by every other day for 6 months). Recurrences as well as adverse events were recorded in all patients. <h3>Results</h3> Among the 11 patient included there were 6 males with a mean age of 42 ± 16.8 years and a median disease duration of 37 months. Patients had a median of 8 recurrences prior to Anakinra initiation and were CS-resistant (mean daily prednisolone dose at baseline: 14.7 ± 7.6 mg). Patients were followed for a period of approximately 3 years (median follow-up time: 35 months). All patients responded initially to Anakinra and all were able to discontinue CS rapidly (median time to discontinuation: 6 weeks). During the long term, follow-up, 3 patients discontinued anakinra (27.5%) and remain free of recurrences without any treatment ever since. Five patients (45%) remain on a reduced dose of Anakinra (once a week n=1, twice a week n=1, three days a week n=1, four days a week n=2). Most recurrences occurred while the dose of Anakinra was reduced from three to two injections per week (mean number of recurrences: 2.2 ± 1.4). Three patients continue on full dose Anakinra (one had started therapy 3 months ago). None of these patients had restarted CS. No significant side effects were seen during the long term follow up of these patients and no patient discontinued therapy due to side effects. <h3>Conclusions</h3> During long term follow-up, Anakinra remains a highly efficacious and safe medication for the treatment of refractory recurrent idiopathic pericarditis in adults. All patients remain CS-free and more than a quarter (27.5%) of them were able to discontinue all therapies. Approximately half remain on a reduced dose Anakinra with excellent disease control. <h3>Acknowledgement</h3> Supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece. <h3>Disclosure of Interest</h3> None declared
Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.
Authors: Esther N. Oliva, Roberto Latagliata, Marco Danova, Iolanda Vincelli, Bianca Rovati, Francesca Ronco, Ida Carmosino, Giorgina Specchia, Massimo Breccia, Stefana Impera, Imma Attolico, Francesco Nobile
Journal: Blood (2006)
Comparison of Clinical and Laboratory Features Between Pediatric Aplastic Anemia and Refractory Cytopenia of Childhood
Authors: Asahito Hama, Atsushi Manabe, Daisuke Hasegawa, Hideki Muramatsu, Yoshiyuki Takahashi, Kenichiro Watanabe, Akira Ohara, Masafumi Ito, Seiji Kojima
Journal: Blood (2015)
Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor Genes
Authors: Gabriela B. Iwanski, Nils H. Thoennissen, Joy Nakitandwe, Patricia Lin, Norihiko Kawamata, Rahul Nahar, Parham Ramezani-Rad, Shann-Ching Chen, Sheila Shurtleff, Daniel Nowak, Christian Ruckert, Martin Dugas, Carsten Bokemeyer, Grazia Fazio, Andrea Biondi, Giovanni Cazzaniga, James R. Downing, Markus Müschen, H. Phillip Koeffler
Journal: Blood (2010)
A Mitochondrially Targeted Nitroxide JP4-039 Protects and Mitigates against Total Body Irradiation Induced Hematopoietic Syndrome
Authors: Michael W Epperly, Joshua G Pierce, Tracy Dixon, Darcy Franicola, Suhua Nie, Xichen Zhang, Irina I Vlasova, Peter Wipf, Valerian Kagan, Joel Greenberger
Journal: Blood (2008)
Overcoming TNF-α Induced Suppression of Erythroid Differentiation of Human Cord Blood CD34+ Cells with Arsenic Trioxide.
Authors: Jong-Ho Won, Hee-Jeong Cheong, Sook-Ja Kim, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taeg Lee, Sung-Kyu Park, Dae-Sik Hong, Hee-Sook Park
Journal: Blood (2005)
AB0151 Anti-Major Vault Protein: A New Autoantibody Prevalent in Systemic Lupus Erythematosus
Authors: P. Budde, S. Vordenbäumen, H.-D. Zucht, P. Schulz-Knappe, M. Schneider
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a complex, multifactorial autoimmune disease that affects multiple organ systems, including the kidney, skin, heart, lung, and hematopoietic and nervous systems. A hallmark of SLE is the production of high titers of autoantibodies against a broad spectrum of antigens. Given the broad spectrum of immune defects in SLE, it may be possible that autoantigens are generated by different pathogenic processes. <h3>Objectives</h3> Broad autoantibody profiling in SLE may yield novel autoantibody targets for and may shed light on pathogenic pathways leading to the generation of autoantigens. <h3>Methods</h3> In the discovery phase the autoantibody reactivity of serum samples from 130 SLE patients, 794 AID patients (systemic sclerosis, rheumatoid arthritis/RA, early RA, ankylosing spondylitis) and 343 healthy controls was tested against 6,912 recombinant human proteins. Following validation in independent SLE samples (n=101), consistent autoantibody reactivity against 46 antigens was found (p-value &lt;0.05 and Cohen9s d effect size &lt;0.3). <h3>Results</h3> A data base search of 46 known and novel SLE-associated antigens revealed that the expression of ten proteins is upregulated by type I interferon (INF) (http://www.interferome.org).Beyond known antigens (TRIM21/Ro52, SSB), we identified a novel autoantibody target MVP with a frequency of 20 -38% in SLE. Interestingly, MVP is the major constituent of the vault particle, the largest known ribonuclear protein complex. Literature data suggest that vaults are involved in a diversity of cellular processes, including multidrug resistance, transport mechanisms, signal transmission, autophagy, immune and radiation response [1]. <h3>Conclusions</h3> MVP is a virus- and INFγ-induced and host factor, which up-regulates type I INF production [2]. Although more studies are needed, our findings suggest a previously undescribed linkage of INF pathways and the generation of autoantigens. <h3>References</h3> Lara PC, Pruschy M, Zimmermann M, Henríquez-Hernández LA (2011). MVP and vaults: a role in the radiation response. Radiation Oncology (London, England). 6:148. Liu S, Hao Q, Peng N, Yue X, Wang Y, Chen Y, Wu J, Zhu Y (2012). Major vault protein: a virus-induced host factor against viral replication through the induction of type-I interferon. Hepatology. 56(1):57–66. <h3>Disclosure of Interest</h3> P. Budde Employee of: Protagen AG, S. Vordenbäumen: None declared, H.-D. Zucht Employee of: Protagen AG, P. Schulz-Knappe Employee of: Protagen AG, M. Schneider: None declared
Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival
Authors: Clinton C. Mason, Jamshid S. Khorashad, Srinivas K. Tantravahi, Todd W. Kelley, Anthony D. Pomicter, Anthony J. Iovino, Kimberly R. Reynolds, Anna M. Eiring, Matthew S. Zabriskie, Zev Kronenberg, Jeffrey W. Tyner, Brian Dalley, Kim-Hien T. Dao, Thomas O'Hare, Mark Yandell, Brian J. Druker, Jason R. Gotlib, Michael W. Deininger
Journal: Blood (2014)
SAT0005 A Meta-Analysis and A Functional Study with Transmitochondrial Cybrids Confirm The Role of The Mtdna Haplogroups in The Development of Incident Knee Osteoarthritis. Data from Check and Oai
Authors: I. Rego-Pérez, M. Fernández-Moreno, A. Soto-Hermida, M.E. Vázquez-Mosquera, E. Cortés-Pereira, S. Relaño, T. Hermida-Gόmez, S. Pértega, N. Oreiro, C. Fernández-Lόpez, R. Garesse, F.J. Blanco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In the last years the study of the mitochondria in the context of osteoarthritis (OA) attracted much attention. In the present work we aim to analyze the role of the mtDNA haplogroups in the development of incident knee OA in well-characterized study cohorts <h3>Objectives</h3> To analyze the influence of the mtDNA haplogroups in the rate of incident knee OA in the prospective cohorts of CHECK and OAI and to perform functional analysis with transmitochondrial cybrids to explore the consequences of the mitochondrial background in the pathogenesis of Osteoarthritis <h3>Methods</h3> The influence of the haplogroups in the development of incident knee OA at eight years in 2579 subjects from the Osteoarthritis Initiative (OAI) and 635 subjects from the Cohort hip and Cohort knee (CHECK) was assessed. A subsequent meta-analysis was conducted to strengthen the association of these individual studies. Transmitochondrial cybrids carrying the haplogroups J and H were constructed to study the influence of the mitochondrial background in different OA-related features. <h3>Results</h3> The haplogroup J significantly associates with a decreased risk of incident knee OA in subjects from the OAI (HR=0.680;95%CI=0.470–0.968;p&lt;0.05) and CHECK (HR=0.728;95%CI=0.469–0.998;p&lt;0.05). The subsequent meta-analysis including 3214 cases showed that the haplogroup J significantly associates with a lower risk of incident knee OA (HR=0.702;95%CI=0.541–0.912;p=0.008) (Figure 1). Compared with the haplogroup H, haplogroup J shows a lower free radical production, specially peroxide/peroxynitrite (52.51±11.34 vs 41.26±7.48;p&lt;0.05) and superoxide (8.58±3.0 vs 4.25±0.9;p&lt;0.05), a higher cell survival under oxidative stress conditions (29.63±3.3 vs 56.45±7.36;p&lt;0.05), a lower grade of apoptosis (7.35±3.78 vs 4.69±1.68;p&lt;0.05) as well as a lower expression of the mitochondrially-related pro-apoptotic gene BBC3 (3.3-fold;p&lt;0.05), a higher lactate production (64.22±10.76mg/dl vs 51.42±6.85mg/dl;p&lt;0.05) and a lower expression of the mitochondrial biogenesis-related gene PGC1-α (2-fold;p&lt;0.05) <h3>Conclusions</h3> The haplogroup J reduces the risk of incident knee OA. This mitochondrial variant constitute a protective phenotype against the development of OA, emerging as a powerful OA biomarker and even leading to the consideration of the mitochondrion as a potential therapeutic target in OA <h3>Acknowledgement</h3> We9d like to acknowledge to the participants of CHECK and OAI cohorts <h3>Disclosure of Interest</h3> None declared
Correlation between Flow Cytometry Immunophenotyping, Chimerism Quantification and IGH Gene Rearrangement Analysis in Disease Associated Leukocyte Lineages after Stem Cell Transplantation in an ALL Patient.
Authors: Mi Kwon, Ismael Buño, Javier Anguita, Diana Barroso, Gustavo Iglesias, David Serrano, Alfonso Gomez-Pineda, Jose L. Diez-Martin
Journal: Blood (2006)
SAT0028 Circulating Surfactant Protein-D (SP-D) Molecular Size Profile Differs between Patients with Untreated Axial Spondyloarthritis and Healthy Control Subjects
Authors: H.L. Munk, D. Fakih, G.L. Sorensen, Q. Tan, L. Christiansen, A.F. Christensen, L. Ejstrup, A.G. Loft, K.O. Kyvik, R. Jounblat, U. Holmskov, P. Junker
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Surfactant protein-D (SP-D), an innate immune defence molecule of the collectin family has immune modulatory and anti-microbial effects and is expressed in lungs and on mucosal surfaces. The molecule consists of subunits ordered as trimers, dodecamers and even higher multimers. In healthy adults genes are responsible for the majority of the quantitative variation of SP-D in serum as well as its molecular size distribution<sup>1</sup>. High Molecular weight (HMw) SP-D is suggested to have anti-inflammatory properties, while low Mw (LMw) variants lack this capacity. In spondyloarthritis (SpA) SP-D correlates negatively with hsCRP and positively with patient global assessment. LMw variants have been shown to prevail in serum during inflammatory flares in chronic obstructive pulmonary disease. <h3>Objectives</h3> To investigate the distribution of SP-D HMw and LMw variants in serum among patients with SpA and controls according to the Met11Thr polymorphism. <h3>Methods</h3> 34 patients with SpA (age 22–63) according to the ASAS criteria, receiving NSAIDs only and 57 healthy controls (age 10–75) were included (Table 1). Total SP-D in serum was measured by ELISA and SNP rs721917 was genotyped. SP-D molecular size distribution was assessed using gel filtration chromatography. Integration of the area under the curves was performed to determine the ratio between HMw and LMw SP-D in serum. <h3>Results</h3> SP-D in SpA was in the normal range, 1092 ng/ml (725;1541) vs. controls, 910 ng/ml (494; 1682). Whereas the ratio of HMw:LMw serum SP-D was lower in SpA patients, 0.38 (0.18;0.53) compared to controls 1.49 (0.37; 3.24) even when adjusting for the Met11Thr polymorphism, gender, age, BMI and smoking (Table 2). <h3>Conclusions</h3> The molecular size distribution of circulating SP-D in patients with SpA is skewed towards preponderance of small size molecular variants. SpA related disease mechanisms may disrupt the multimeric state of SP-D, thereby amplifying the inflammatory burden of the disease. <h3>References</h3> Leth-Larsen R. J Immunol 2005;174:1532–8 <h3>Disclosure of Interest</h3> None declared
Low Dose Busulfan Is Associated with Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Lee Gazourian, Angela J Rogers, Ruby Igbanga, Gerald L Weinhouse, Robert J Soiffer, Joseph H Antin, Jerome Ritz, Vincent T Ho, George R Washko, Rebecca M Baron
Journal: Blood (2012)
Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.
Authors: Patrizia Tosi, Elena Zamagni, Claudia Cellini, Delia Cangini, Paola Tacchetti, Giulia Perrone, Sante Tura, Michele Baccarani, Michele Cavo
Journal: Blood (2004)